{"title":"直接选择性激光小梁成形术治疗青光眼。","authors":"Tim Schultz, Atanas Bogoev, H Burkhard Dick","doi":"10.1007/s00347-025-02315-6","DOIUrl":null,"url":null,"abstract":"<p><p>Glaucoma is one of the leading causes of irreversible blindness. Pharmacological first-line therapies are limited by poor patient adherence. Selective laser trabeculoplasty (SLT) offers effective reduction of intraocular pressure (IOP). Direct selective laser trabeculoplasty (DSLT) represents an advancement, enabling automated and contactless treatment for the first time. It could become established as the first-line therapy in the future.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Direct selective laser trabeculoplasty for glaucoma].\",\"authors\":\"Tim Schultz, Atanas Bogoev, H Burkhard Dick\",\"doi\":\"10.1007/s00347-025-02315-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Glaucoma is one of the leading causes of irreversible blindness. Pharmacological first-line therapies are limited by poor patient adherence. Selective laser trabeculoplasty (SLT) offers effective reduction of intraocular pressure (IOP). Direct selective laser trabeculoplasty (DSLT) represents an advancement, enabling automated and contactless treatment for the first time. It could become established as the first-line therapy in the future.</p>\",\"PeriodicalId\":72808,\"journal\":{\"name\":\"Die Ophthalmologie\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Die Ophthalmologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00347-025-02315-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Die Ophthalmologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00347-025-02315-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Direct selective laser trabeculoplasty for glaucoma].
Glaucoma is one of the leading causes of irreversible blindness. Pharmacological first-line therapies are limited by poor patient adherence. Selective laser trabeculoplasty (SLT) offers effective reduction of intraocular pressure (IOP). Direct selective laser trabeculoplasty (DSLT) represents an advancement, enabling automated and contactless treatment for the first time. It could become established as the first-line therapy in the future.